Pharmaceutical CompanyEli Lilly and Company, Puerto Rico, USA
Form:Tablet
Contents:Product description
General:
Company:
Company(s) in Each Country:
Description:Eli Lilly and Company (NYSE: LLY) is a pharmaceutical company headquartered in the United States in Puerto Rico, Puerto Rico, and the Philippines. Its product portfolio includes over 200 brands and more than 150 generics. Its products range from non-steroidal anti-inflammatory drugs (NSAIDs) to branded generic products. This includes prescription and over-the-counter (OTC) drugs, as well as dietary supplements.
Key features:
Company-specific-
Company-specific OTC products:For example, the company's product, AbbVie, offers the OTC versions of certain popular medications and lifestyle drugs. This is a broader portfolio of OTC drugs and OTC medications than the company's products.
Company-specific dietary supplements:In certain cases, the company's product may have specific dietary supplements. For instance, the company's products include products in the dietary supplements of high blood pressure, diabetes, and cholesterol.
In certain cases, the company's product may also have specific dietary supplements. For instance, the company's products include products in the dietary supplements of weight loss and energy.
Company-specific health benefits:For example, the company's product, Nexium, offers the company's products' cholesterol-lowering and diabetes-reducing effects. This is a broader portfolio of health benefits than the company's products.
Company-specific benefits:For example, Nexium is one of the company's health benefits for certain individuals. This includes its cholesterol-lowering and diabetes-reducing effects.
Company-specific information:For instance, Nexium is the company's company information for consumers and doctors. It includes a variety of company-specific information.
For instance, Nexium is the company information for consumers and doctors.
Company-specific products:For instance, the company's product, Nexium 24HR, offers the company's products' cholesterol-lowering and diabetes-reducing effects.
For instance, Nexium 24HR is the company information for consumers and doctors.
Company-specific product:Eli Lilly and Company provides a variety of pharmaceutical products, including brand-name drugs, non-steroidal anti-inflammatory drugs (NSAIDs), and other non-prescription and prescription products.
The company's products include drugs from different types of cancer, blood pressure medications, blood thinners, pain relievers, anticoagulants, and other prescription drugs.
Eli Lilly and Company provides a variety of pharmaceutical products, including drugs for cancer, blood pressure medications, blood thinners, pain relievers, anticoagulants, and other prescription and over-the-counter (OTC) drugs.
The global market for Nexium is estimated to be worth US$10.8 billion by 2033, growing at a CAGR of 7.6% during the forecast period.
The global market for Nexium is expected to reach US$16.9 billion by 2027, growing at a CAGR of 7.6% during the forecast period.
The market for esomeprazole magnesium tablets has been undergoing a significant transformation in recent years. This segment is expected to witness a rapid growth in its market size in the coming years. The growth of the esomeprazole market in the global esomeprazole market is expected to be driven by several factors.
The global esomeprazole market is segmented into different types of esomeprazole brands. The esomeprazole market is segmented into the following groups:
Esomeprazole is the main brand of esomeprazole used in the treatment of gastroesophageal reflux disease (GERD) and related disorders.
The market is dominated by esomeprazole containing products which have a high esomeprazole concentration. The market is segmented by the number of brands, concentration, and gender.
The global esomeprazole market is expected to reach US$16.9 billion by 2027, growing at a CAGR of 7.6% during the forecast period. The global esomeprazole market is expected to grow at a CAGR of 7.6% from 2024 to 2027. The market is expected to be affected by various factors such as
- the rapid growth of the esomeprazole market in the global esomeprazole market, the impact of technological advancements, and the increasing prevalence of GERD and other disorders in the population.
- the growing incidence of GERD and related disorders in the population, along with an increasing prevalence of GERD and related disorders in the general population.
- the global prevalence of gastroesophageal reflux disease (GERD) in adults and the growing prevalence of GERD in children and adults.
- the growing incidence of chronic acid reflux disease (GERD) and related disorders in adults and the growing prevalence of GERD in children.
The market is expected to grow at a CAGR of 7.6% during the forecast period. The global esomeprazole market is segmented into the following groups:
Esomeprazole is a generic product for the treatment of GERD and related disorders. The market is segmented into esomeprazole containing products that have a high esomeprazole concentration. The market is segmented into esomeprazole containing products containing the active ingredient esomeprazole magnesium.
Esomeprazole is the main brand of esomeprazole used in the treatment of GERD and related disorders.
The global esomeprazole market is expected to be affected by various factors including the impact of technological advancements, the growing incidence of GERD and related disorders, and the increasing prevalence of GERD in the general population.
The global esomeprazole market is expected to be affected by the presence of various factors such as
- the rapid growth of the esomeprazole market, the rising incidence of GERD, the growing prevalence of GERD in adults, and the increasing prevalence of GERD in children.
- the global prevalence of GERD in adults, the increasing prevalence of GERD in children, the growing incidence of chronic acid reflux disease (GERD), and the growing incidence of chronic acid reflux disease (GERD) in children.
- the global esomeprazole market is expected to grow at a CAGR of 7.6% during the forecast period. The global esomeprazole market is expected to be affected by various factors, including the presence of various factors, and the growing incidence of GERD in adults.
The market is segmented into the following categories:
PITTSBURGH,March 20, 2015/PRNewswire/ -- Merck & Co. Inc. (NYSE: MRK) today announced it has entered into a definitive agreement with Pfizer Inc. (NYSE: PFE) to develop a new gastrointestinal, cardiovascular, psychiatric and neuroscience product, Nexium (esomeprazole), and a product for treating conditions of diabetes in conjunction with other medications. The agreement, which is subject to regulatory approval for marketing, will provide Merck with exclusivity for the development of Nexium for human use.
Pfizer Inc. (NYSE: PFE) was one of the first pharmaceutical companies to file for approval for Nexium for human use in the United States in the year ended December 31, 2003. Under the agreement, Pfizer will continue to provide marketing, testing, and sales of its Nexium product for use in humans through December 31, 2005. Under the agreement, Pfizer will make royalties on Nexium sales through the end of 2006 and continue to make payments to Merck for the benefit of the product. Under the agreement, Pfizer will also be responsible for the development and commercialization of all Nexium product in the United States, and that the development of the product will be done under the direction of Merck. The agreement further provides that the product will be developed and commercialized in the United States in the first quarter of 2006. Under the agreement, Merck will continue to make payments to Merck for the benefit of Nexium. The agreement also provides that Pfizer is not liable for any damages to patients who suffer from heart failure, and that Merck is not responsible for any damages caused by Nexium or any medical device that was not used in the development of any Nexium product, and that no milestone payments may be made to Merck based upon the product being developed. The agreement further provides that Pfizer does not have any right, under any law, to the patent rights of any of its own competitors.
Pfizer, Inc. (NYSE: PFE) today announced that it has entered into a definitive agreement with Pfizer to develop a gastrointestinal, cardiovascular, psychiatric and neuroscience product, Nexium (esomeprazole), and a product for treating conditions of diabetes in conjunction with other medications. The agreement, which is subject to regulatory approval for marketing, testing, and sales of its Nexium product for use in humans through December 31, 2005, will provide Merck with exclusivity for the development of Nexium for human use through December 31, 2005 and further provide that Merck will make royalties on Nexium sales through the end of 2006 and continue to make payments to Merck for the benefit of Nexium. Under the agreement, Pfizer will make royalties on Nexium sales through the end of 2006 and also make payments to Merck for the benefit of Nexium. Under the agreement, Pfizer will not make any payments to Merck based upon Nexium being developed and commercialized in the United States.
The agreement, which is subject to regulatory approval for marketing, testing, and sales of its Nexium product for use in humans through December 31, 2005, will provide Merck with exclusivity for the development of Nexium for human use through December 31, 2005 and further provide that Merck will make royalties on Nexium sales through the end of 2006 and further provide that Merck will make payments to Merck for the benefit of Nexium. The agreement further provides that Pfizer is not liable for any damages to patients who suffer from heart failure, and that Merck is not responsible for any damages caused by Nexium or any medical device that was not used in the development of any Nexium product, and that no milestone payments may be made to Merck based upon the product being developed. The agreement also provides that Pfizer does not have any right, under any law, to the patent rights of any of its own competitors.
Nexium, the brand name for esomeprazole magnesium, is a prescription medicine used to treat certain types of stomach conditions. It is also used to treat high blood pressure, heartburn and ulcers caused by certain stomach acids. Esomeprazole magnesium belongs to a class of medications called proton pump inhibitors (PPIs). It works by decreasing the amount of acid produced in the stomach, thus helping to alleviate symptoms of stomach and ulcers. Nexium is available in the form of a capsule that is swallowed with water.
Nexium is used to treat conditions such as:
Nexium works by decreasing the amount of acid produced in the stomach, thus helping to relieve symptoms of acid reflux, heartburn and indigestion. Esomeprazole magnesium is a proton pump inhibitor that also acts as an antacid that dissolves in the mouth to help prevent stomach acid from being broken down in the stomach.
Nexium is generally well tolerated, but it can cause side effects such as:
Nexium and other proton pump inhibitors can help relieve symptoms of stomach and ulcers caused by acid reflux. Nexium, a brand name for esomeprazole magnesium, is a proton pump inhibitor that works by decreasing the amount of acid produced in the stomach, which is necessary for the absorption of acid from food. Nexium is available in the form of a capsule and tablet that is swallowed with a glass of water. Nexium is also available as an oral tablet, and can be taken with or without food.
Nexium may also be used to treat certain types of stomach disorders such as:
Nexium is also used to treat conditions such as:
Nexium is available as a capsule and tablet. The dosage of Nexium varies depending on the condition being treated, the patient's age, and their medical history. The patient's symptoms can include:
Stade de France Pharmacy